Rigel settles TAVALISSE patent litigation with Annora; generic entry in Q2 2032

RIGEL PHARMACEUTICALS INC

Entered settlement with Annora Pharma, Hetero Labs, and Hetero USA resolving patent litigation on TAVALISSE (fostamatinib).
Annora receives license to sell generic version in Q2 2032 or earlier under certain circumstances.
All ongoing litigation between Rigel and Annora in New Jersey terminated.
CEO Raul Rodriguez cites resolution as underscoring strength of TAVALISSE intellectual property.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.